organ
transplant
becom
primari
treatment
patient
endstag
organ
failur
although
applic
immunosuppress
drug
contribut
significantli
success
allograft
surviv
side
effect
result
immunosuppress
drug
toxic
also
markedli
impact
qualiti
life
recipi
therefor
establish
strategi
aim
induc
allograft
toler
want
set
transplant
dc
activ
mediat
graft
reject
present
donorderiv
alloantigen
cell
howev
emerg
evid
indic
mediat
allograft
reject
dc
also
possess
capabl
induc
allograft
toler
therefor
dc
capabl
induc
either
immun
respons
toler
depend
activ
matur
statu
member
tyrosinekinas
receptor
famili
initi
clone
fetal
liver
cell
hematopoiet
stem
cell
activ
ligand
key
regul
dc
commit
develop
mice
administ
display
expans
certain
subtyp
dc
plasmacytoid
dc
pdc
convent
dc
cdc
spleen
studi
shown
pdc
play
import
role
induct
treg
vivo
manifest
precursor
abl
prolong
graft
surviv
studi
hematopoiet
cell
transplant
also
reveal
potent
mobil
induc
murin
hematopoiet
chimer
longterm
persist
donor
hematopoiet
cell
peripher
lymphoid
nonlymphoid
tissu
organ
allograft
recipi
postul
essenti
prerequisit
induct
donorspecif
toler
autophagi
eukaryot
cell
cellular
qualiti
control
process
deliv
cytoplasm
constitu
lysosom
degrad
enabl
cell
recycl
nutrient
surviv
nutrient
starvat
rapamycin
inhibitor
mammalian
target
rapamycin
mtor
use
stimul
autophagi
steadi
state
autophagymedi
antigen
process
thymic
epitheli
cell
could
crucial
role
induct
mainten
tcell
toler
studi
examin
effect
combin
rapamycin
cardiac
allograft
model
result
demonstr
combin
lowdos
rapamycin
prevent
acut
allograft
reject
prolong
allograft
surviv
time
enhanc
allograft
surviv
associ
induct
tolerogen
dc
along
product
regulatori
cell
increas
allograft
autophagi
data
suggest
combin
lowdos
rapa
could
promis
therapeut
strategi
clinic
transplant
first
sought
investig
regulatori
effect
combin
shortterm
lowdos
rapa
treatment
allograft
acut
reject
murin
cardiac
allograft
transplant
model
employ
address
question
shown
figur
untreat
recipi
rapidli
reject
graft
day
along
typic
patholog
featur
acut
reject
fig
similar
patholog
featur
observ
recipi
treat
either
pb
rgst
control
figur
expect
administr
rapa
significantli
increas
graft
mean
surviv
time
mst
day
fig
similarli
recipi
treat
doubl
allograft
mst
day
fig
sharp
contrast
signific
enhanc
graft
surviv
observ
mice
treat
lowdos
rapa
day
fig
remark
recipi
show
longterm
graft
surviv
mst
day
fig
consist
result
signific
reduct
inflammatori
infiltr
observ
allograft
section
fig
next
examin
dc
phenotyp
recipi
mice
note
signific
increas
number
pdc
mice
treat
lowdos
rapa
compar
control
mice
fig
similarli
also
detect
significantli
higher
proport
splenic
dc
treat
mice
fig
sinc
dc
pdc
regulatori
function
data
suggest
rapa
could
induc
expans
regulatori
dc
recipi
mice
rapamycin
shown
inhibit
upregul
matur
marker
express
dc
immatur
dc
demonstr
capabl
prolong
allograft
surviv
line
notion
combin
rapa
significantli
block
dc
matur
manifest
decreas
express
fig
sinc
pdc
previous
report
potent
induc
treg
investig
whether
pdc
implic
induct
allograft
toler
inde
recipi
treat
lowdos
rapa
display
signific
increas
pdc
compar
recipi
treat
rapa
alon
group
fig
result
prompt
us
examin
proport
treg
end
splenic
cell
isol
group
recipi
mice
stain
intracellular
costain
antibodi
antibodi
cell
next
analyz
flow
cytometri
signific
increas
treg
observ
recipi
treat
rapa
compar
recipi
group
fig
test
reactiv
bulk
cell
isol
spleen
recipi
donorderiv
dc
shown
figur
cell
deriv
treat
mice
exhibit
significantli
lower
prolif
respons
donor
balbc
dc
mlr
compar
cell
deriv
untreat
rgsttreat
pbstreat
recipi
unexpectedli
similar
prolifer
rate
note
recipi
treat
either
rapa
alon
compar
recipi
treat
result
promot
us
examin
cytokin
product
cultur
supernat
elisa
interestingli
note
product
significantli
higher
treat
mice
importantli
although
cell
deriv
rapa
treat
mice
show
similar
potenc
prolifer
fig
capac
secret
similar
cell
control
mice
fig
collect
data
suggest
treatment
enhanc
secret
could
favor
induct
anergi
given
therapi
result
reproduc
longterm
allograft
surviv
recipi
without
immunosuppress
fig
thu
employ
adopt
transfer
studi
character
cell
subpopul
sustain
allograft
surviv
purpos
cell
cell
pdc
total
splenocyt
first
isol
longterm
surviv
recipi
adopt
transfer
naiv
recipi
mice
next
transplant
cardiac
allograft
describ
shown
figur
transfer
cell
pdc
exhibit
abil
prolong
allograft
surviv
unexpectedli
compar
cell
pdc
adopt
transfer
cell
fail
provid
protect
allograft
reject
determin
whether
prolong
allograft
surviv
associ
enhanc
autophagi
examin
level
autophagyrel
protein
microtubul
associ
light
chain
ii
western
blot
analysi
shown
fig
low
level
ii
detect
control
mice
rgst
untreat
pb
group
higher
level
ii
observ
mice
treat
rapa
alon
importantli
highest
ii
express
note
treat
mice
confirm
result
immunohistochem
analysi
similar
result
obtain
fig
examin
function
relev
enhanc
autophagi
allograft
surviv
perform
similar
transplant
along
administr
autophagi
inhibitor
expect
administr
significantli
repress
autophagi
determin
western
blot
immunohitochem
analysi
fig
remark
repress
autophagi
significantli
attenu
therapi
mediat
protect
allograft
reject
fig
consist
result
also
observ
decreas
number
regulatori
cell
regulatori
dc
fig
taken
togeth
data
indic
autophagi
play
essenti
role
therapi
mediat
protect
allograft
reject
summari
combin
rapamycin
abl
promot
prolong
allograft
surviv
protect
effect
associ
gener
tolerogen
dc
subset
regulatori
cell
treg
enhanc
allograft
autophagi
six
eight
weekold
femal
balbc
mice
obtain
anim
facil
tongji
medic
colleg
mice
maintain
specif
pathogenfre
condit
studi
carri
complianc
institut
anim
care
use
guidelin
cfse
purchas
invitrogen
eugen
usa
kit
obtain
follow
mous
elisa
delux
deriv
biolegend
mous
microbead
miltenyi
biotec
ca
mous
plasmacytoid
dendrit
cell
isol
kit
ii
miltenyi
biotec
ca
mous
microbead
deriv
miltenyi
biotec
ca
rapamycin
purchas
wyeth
usa
purchas
sigma
antibodi
purchas
cell
signal
antimous
clone
antimous
clone
fitclabel
antimous
clone
pelabel
antirat
clone
antimous
clone
apclabel
antimous
clone
apclabel
antimous
clone
antimous
clone
fitclabel
antimous
clone
pelabel
antimous
clone
antimous
clone
apclabel
antimouserat
clone
obtain
ebiosci
san
diego
ca
usa
dna
sequenc
encod
bp
amplifi
mous
spleen
cdna
use
follow
oligonucleotid
gat
cca
tga
cag
tgc
tgg
cgc
aat
tca
tcc
tag
gga
tgg
result
product
subsequ
clone
vector
glutathion
stransferas
tag
plasmid
transform
escherichia
coli
strain
recombin
express
induc
addit
mm
iptg
purifi
use
glutathion
sepharos
resin
column
instruct
manufactur
gst
vector
protein
also
express
purifi
homogen
protein
pass
polymyxin
b
column
pierc
remov
contamin
lp
concentr
micropor
filter
purifi
recombin
rgst
store
aliquot
use
heterotop
cardiac
transplant
perform
previous
describ
studi
transplant
surgeri
involv
transfer
fulli
mhcmismatch
heart
balbc
donor
recipi
heart
beat
graft
monitor
evalu
daili
direct
abdomin
palpat
detect
state
cardiac
healthreject
heart
transplant
recipi
randomli
assign
six
group
n
group
rgst
alon
group
untreat
control
group
pb
alon
group
alon
iv
consecut
day
heart
transplant
group
rapa
alon
mgkgday
po
group
combin
treatment
rapa
allograft
sampl
fix
paraformaldehyd
serial
section
thick
prepar
use
microtom
stain
hematoxylineosin
analysi
patholog
chang
spleen
cell
isol
mice
treat
control
mice
incub
monoclon
antibodi
block
fcr
stain
antimous
mab
antimous
mab
mab
fitclabel
antimous
mab
apclabel
antimous
mab
apclabel
antimous
mab
gate
dc
analyz
flow
cytometri
express
variou
dc
marker
analysi
regulatori
cell
splenocyt
isol
recipi
mice
subsequ
costain
antibodi
cell
stain
use
establish
techniqu
cell
analyz
use
fac
flow
cytomet
previous
report
splenic
cell
purifi
use
nylon
wool
column
isol
naiv
graft
mice
serv
respond
incub
day
presenc
mitomycin
ctreat
sigmaaldrich
dc
use
stimul
deriv
naiv
balbc
mice
dc
ratio
flat
bottom
plate
nunc
roskild
denmark
cultur
kept
atmospher
supernat
recov
day
determin
product
cytokin
level
quantifi
use
mous
elisa
delux
tcell
prolifer
assess
serial
dilut
intracellular
cfse
dye
describ
previous
protein
extract
cardiac
allograft
subject
electrophoresi
transfer
onto
pvdf
membran
membran
incub
primari
antibodi
gapdh
h
respect
blot
visual
use
enhanc
chemiluminesc
amersham
deparaffin
rehydr
paraffinembed
heart
section
treat
min
nonspecif
protein
block
goat
serum
min
stain
specimen
incub
rabbit
antimous
monoclon
antibodi
overnight
follow
incub
hrp
conjug
goat
antirabbit
secondari
antibodi
section
final
incub
dab
chromogen
substrat
counterstain
hematoxylin
total
cell
first
enrich
cell
use
nylon
wool
column
subject
isol
mous
cell
use
microbead
cell
use
mous
microbead
instruct
miltenyi
biotec
ca
pdc
isol
use
mous
plasmacytoid
dendrit
cell
isol
kit
ii
instruct
miltenyi
biotec
ca
purifi
cell
cell
pdc
total
splenocyt
origin
recipi
longterm
surviv
allograft
adopt
transfer
naiv
recipi
respect
one
day
adopt
transfer
mice
transplant
cardiac
allograft
monitor
allograft
surviv
describ
data
present
mean
sd
statist
differ
determin
oneway
anova
allograft
surviv
differ
group
determin
use
logrank
test
p
valu
less
consid
statist
signific
